NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more
NanoRepro AG - Asset Resilience Ratio
NanoRepro AG (NN6) has an Asset Resilience Ratio of 19.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how NanoRepro AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down NanoRepro AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €7.29 Million | 19.19% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €7.29 Million | 19.19% |
Asset Resilience Insights
- Good Liquidity Position: NanoRepro AG maintains a healthy 19.19% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
NanoRepro AG Industry Peers by Asset Resilience Ratio
Compare NanoRepro AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for NanoRepro AG (2010–2024)
The table below shows the annual Asset Resilience Ratio data for NanoRepro AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.31% | €9.10 Million | €39.03 Million | -26.43pp |
| 2023-12-31 | 49.74% | €20.62 Million | €41.46 Million | -13.44pp |
| 2022-12-31 | 63.18% | €31.26 Million | €49.48 Million | +27.78pp |
| 2021-12-31 | 35.40% | €28.02 Million | €79.15 Million | +24.98pp |
| 2020-12-31 | 10.42% | €1.16 Million | €11.17 Million | -4.93pp |
| 2019-12-31 | 15.35% | €737.15K | €4.80 Million | -15.13pp |
| 2018-12-31 | 30.48% | €1.77 Million | €5.81 Million | +17.90pp |
| 2017-12-31 | 12.58% | €528.05K | €4.20 Million | -2.51pp |
| 2016-12-31 | 15.09% | €530.12K | €3.51 Million | +14.98pp |
| 2010-12-31 | 0.11% | €2.15K | €1.94 Million | -- |